The new anti-amyloid drugs for AD are interesting, but an efficacy of 3 points on a 144 scale (2%) does not sound so impressive. We also need to understand ARIA much more
Læs også
@JoachimTHP @regionerne @LMSTdk Ja, og fint hvis man kunne lave et nordisk samarbejde her, der sikrede forsyningen af nogle af
- Andreas Andersen
- 21. januar 2022
- 0
@JoachimTHP @regionerne @LMSTdk Ja, og fint hvis man kunne lave et nordisk samarbejde her, der sikrede forsyningen af nogle af de vigtigste lægemidler
@lars_kunstmann @DFredsgaard @regeringen @SSTbrostrom Ja bestemt – men tallet 1/40.000 er også højere end jeg hørte til at starte med.
- Andreas Andersen
- 14. april 2021
- 0
@lars_kunstmann @DFredsgaard @regeringen @SSTbrostrom Ja bestemt – men tallet 1/40.000 er også højere end jeg hørte til at starte med. Og der findes andre vacciner […]
@Catobagger @kasper2619 @me_marco @Heunicke COVID-19 er blevet associeret med en øget forekomst for blodpropper, men det er ikke det samme.
- Andreas Andersen
- 20. april 2021
- 0
@Catobagger @kasper2619 @me_marco @Heunicke COVID-19 er blevet associeret med en øget forekomst for blodpropper, men det er ikke det samme. Forebyggelsen, behandlingen og risikoen er […]
Agree that we need to characterize ARIA better and make sure doctors know how to predict it and manage it. On the efficacy, I struggle to see why such a change ( which is measurable and consistent on a clinical scale which is not so sensitive to begin with) should be meaningless.
If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.